29.34
+0.41(+1.42%)
Currency In USD
| Previous Close | 28.93 |
| Open | 28.24 |
| Day High | 29.5 |
| Day Low | 28.24 |
| 52-Week High | 32.35 |
| 52-Week Low | 5.66 |
| Volume | 100,311 |
| Average Volume | 175,754 |
| Market Cap | 485.22M |
| PE | -1.98 |
| EPS | -14.8 |
| Moving Average 50 Days | 18.54 |
| Moving Average 200 Days | 11.41 |
| Change | 0.41 |
If you invested $1000 in RAPT Therapeutics, Inc. (RAPT) since IPO date, it would be worth $282.12 as of October 19, 2025 at a share price of $29.34. Whereas If you bought $1000 worth of RAPT Therapeutics, Inc. (RAPT) shares 5 years ago, it would be worth $100.18 as of October 19, 2025 at a share price of $29.34.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
GlobeNewswire Inc.
Sep 29, 2025 9:00 AM GMT
RAPT on track to initiate trial this yearSOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and comm
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 27, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients l
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
GlobeNewswire Inc.
Jun 23, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients l